| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39bf0bb8b07e151d4bcead749d7dd699 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-08 |
| filingDate |
2012-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70372b70eecbed6bdb57e9c54287c14a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6307141225dd82af8fa0cf43cba03d61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_890d10641db2d921679c2fa121a716f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a851c82d752d7edba6800dfc6953c87a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75b44ded7133d740aa396e8eb32bd78f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5b84da5dfe846810fbf726f03cc69a6 |
| publicationDate |
2017-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9694063-B2 |
| titleOfInvention |
Clostridium difficile toxin-based vaccine |
| abstract |
The present invention relates to recombinant fragments of C. difficile TcdA and TcdB that may be used in the development of vaccines against C. difficile associated disease. More particularly it relates to combinations comprising a ToxB-GT antigen and a TcdA antigen or a ToxA-GT antigen and a TcdB antigen. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11535652-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10787652-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10774117-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208633-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10933126-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11129906-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019112584-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10982198-B2 |
| priorityDate |
2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |